Search results
Results from the WOW.Com Content Network
It marks the second large deal for AbbVie in the past week, coming days after it agreed to buy cancer drug developer ImmunoGen for $10.1 billion in cash, highlighting its appetite to place big ...
For AbbVie, the 200-day moving average sits at $176.24, according to Benzinga Pro, which is below the current price of $189.49. For more on charts and trend lines, see a description here.
AbbVie has offered $31.26 per share in cash, representing a premium of 94.6% to Immuogen stock's last close. Immunogen's shares surged 82% to a near 23-year high of $29.34 in early trading.
Disappointing news from the laboratory weighed on AbbVie (NYSE: ABBV) stock as the trading week kicked off. The company had high hopes for a schizophrenia drug it was developing; however, it did ...
AbbVie will pay around $10 billion to add a potential blockbuster cancer treatment as cheaper versions of the drugmaker’s all-time best seller, Humira, cut into sales. The company said it will ...
AbbVie has also agreed to pay Landos shareholders an additional up to $11.14 per share, or around $75 million in total, contingent on certain clinical development milestones.
AbbVie Inc is nearing an approximately $8 billion deal to acquire Cerevel Therapeutics Holdings Inc, a developer of drugs for neurological conditions such as Parkinson's, people familiar with the ...
AbbVie Inc is likely to beat Wall Street sales estimates for Humira in the second quarter as the only copycat in the U.S. market for the blockbuster arthritis drug struggled to gain traction.